SPAC combinationOct 26, 2026Pending
🇺🇸 United States
CPCorxel Pharmaceuticals, Inc.AAAmanat Acquisition Corp
Healthcare › Biotechnology
Deal valueUndisclosed
AnnouncedOct 26, 2026
ConsiderationStock
StructureOther
RegionNorth America
Cross-borderNo
Contingent paymentNo
Overview
Amanat Acquisition Corp agreed to combine with Corxel Pharmaceuticals, Inc. in a SPAC business combination, with Corxel US becoming a wholly owned subsidiary of the combined public company and Corxel Group receiving equity consideration in common stock and pre-funded warrants.
Deal rationale
The transaction is intended to create a publicly listed obesity-focused biopharmaceutical company with capital to advance Corxel US's oral obesity franchise, including CX11 and CX12.
AI-generated from the SEC filingPendingHealthcare › BiotechnologyUnited StatesNorth America
Timeline
Valuation and terms
| Equity value | Undisclosed | |
|---|---|---|
| Enterprise value | Undisclosed | |
| Consideration | Stock |
Advisors
Buy-side
LPLeerink Partners
Sell-side
None listed
Parties
Target
CPCorxel Pharmaceuticals, Inc.
- Headquarters
- United States
- Ticker
- —
Acquirer
AAAmanat Acquisition Corp
- Headquarters
- United States
- Ticker
- —